Dermata Therapeutics, Inc. (DRMA)

Compare

0.9997

-0.0803

(-7.44%)

At close: April 1 at 4:00:01 PM EDT

1.0000

+0.00

+(0.03%)

After hours: April 1 at 7:59:56 PM EDT

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, ...

ACCESS Newswire 5 days ago

DRMA
-7.44%
DRMAW
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARITM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events

PR Newswire 5 days ago

DRMA
-7.44%
DRMAW
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 - - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance ...

ACCESS Newswire 15 days ago

DRMA
-7.44%
DRMAW
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the last patient has completed their last visit in the Company's first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The Company remains on track to annou

PR Newswire 28 days ago

DRMA
-7.44%
DRMAW
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study ...

ACCESS Newswire last month

DRMA
-7.44%
DRMAW
Dermata to Present on BioPub on January 31, 2025

- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community - SAN DIEGO, CA / ACCESS Newswire / January 29, 2025 /Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ...

ACCESS Newswire 2 months ago

DRMA
-7.44%
DRMAW
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESS Newswire / January 23, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, ...

ACCESS Newswire 2 months ago

DRMA
-7.44%
DRMAW
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has entered into definitive ...

ACCESS Newswire 2 months ago

DRMA
-7.44%
DRMAW
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyperhidrosis - If successful, the Companies may explore clinical development in additional indications - Xyngari™ with Daxxify® ...

ACCESS Newswire 2 months ago

DRMA
-7.44%
DRMAW
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that it received approval from ...

ACCESS Newswire 3 months ago

DRMA
-7.44%
DRMAW
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 /Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, ...

ACCESS Newswire 3 months ago

DRMA
-7.44%
DRMAW
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 /Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, ...

ACCESS Newswire 3 months ago

DRMA
-7.44%
DRMAW
Life Sciences Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held November 14th are now available for online viewing. REGISTER NOW AT: https://bit.ly/4fMrinK The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download inve

GlobeNewswire 4 months ago

DRMA
-7.44%
DRMAW

NRBO
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

- Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Raised $5.1 million in gross proceeds ...

ACCESS Newswire 4 months ago

DRMA
-7.44%
DRMAW
Life Sciences Investor Forum Agenda Announced for November 14th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum to be held November 14th. This event is co-sponsored by Zacks SCR. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/3ConPxu It is recommended that inv

GlobeNewswire 4 months ago

ZVSA
-6.54%
NRBO

DRMA
-7.44%
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

– Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com –SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) (“Dermata” or the “Company”), a late-stage biotechnology company focused on the treatment of medical and aesthetics skin diseases and conditions, today announced that Gerry Proehl, Chairman, President, and Chief Executive Officer, will present live

GlobeNewswire 4 months ago

DRMA
-7.44%
DRMAW
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, ...

ACCESS Newswire 5 months ago

DRMA
-7.44%
DRMAW
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata raises approximately $7.8 million in gross proceeds since May 2024 - expected to fund its operations into the second quarter of 2025 SAN DIEGO, CA / ACCESSWIRE / September 17, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," ...

ACCESS Newswire 6 months ago

DRMA
-7.44%
DRMAW
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / September 16, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, ...

ACCESS Newswire 6 months ago

DRMA
-7.44%
DRMAW
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today ...

ACCESS Newswire 6 months ago

DRMA
-7.44%
DRMAW

Performance Overview

Return	DRMA	S&P 500 (^GSPC)
YTD	-25.95%	-4.23%
1-Year	-84.02%	+7.42%
3-Year	-99.67%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata to Present on BioPub on January 31, 2025

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Life Sciences Investor Forum Agenda Announced for November 14th

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Performance Overview